3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Dermatologic
1
Conditions
Vomiting
2
Testicular Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Melanoma
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
75
Nivolumab
46
Cyclophosphamide
25
aldesleukin
23
fludarabine
16
atezolizumab
15
Ipilimumab
15
Interleukin-2
14
Radiosurgery
13
Paclitaxel
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
11
Carboplatin
11
fludarabine phosphate
9
Docetaxel
9
durvalumab
8
Cisplatin
8
cemiplimab
7
Bevacizumab
7
Radiotherapy
6
Gemcitabine
6
Biopsy
6
spartalizumab
5
avelumab
5
Pemetrexed
5
Oxaliplatin
5
Immune Checkpoint Inhibitors
5
Filgrastim
5
Cryosurgery
5
Blood Specimen Collection
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
fosaprepitant
×
Genitourinary
×
Clear all
NCT01874119
2018-06-07
HDIL2/Emend
St. Louis University
Phase 2
Terminated
13 enrolled
7 charts